论文部分内容阅读
现已发现,许多实体瘤表达或高表达表皮生长因子受体(EGFR)。肺癌中,EGFR的异常表达主要出现于非小细胞肺癌(NSCLC)中。反常的信号转导导致这些肿瘤的生长和再生,因此,EGFR信号转导通路的阻滞是抗肿瘤治疗的理想目标。Gefitinib是口服的小分子EGFR酪氨酸激酶抑制剂。西方和日本对Ge-fitinib的耐受性和有效性已有较广泛的研究,但目前对中国患者研究较少。本研究旨在评估Gefitinib用于单一治疗进展期NSCLC中国患者的安全性和疗效性。
It has been found that many solid tumors express or overexpress epidermal growth factor receptor (EGFR). In lung cancer, abnormal expression of EGFR mainly occurs in non-small cell lung cancer (NSCLC). Abnormal signal transduction leads to the growth and regeneration of these tumors, therefore, the blockade of the EGFR signaling pathway is an ideal target for anti-tumor therapy. Gefitinib is an oral small-molecule EGFR tyrosine kinase inhibitor. There has been a wide range of studies on the tolerability and effectiveness of Ge-fitinib in the West and Japan, but few studies have been conducted on Chinese patients. The aim of this study was to evaluate the safety and efficacy of Gefitinib in monotherapy of Chinese patients with advanced NSCLC.